GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Acadia Pharmaceuticals Inc. (ACAD) [hlAlert]

Rating:
Buy ACAD
up 151.39 %

Acadia Pharmaceuticals Inc. (ACAD) rated Buy

Posted on: Tuesday,  Aug 21, 2007  9:25 AM ET by Deutsche Securities

Deutsche Securities rated Buy Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) on 08/21/2007, when the stock price was $15.08. Since
then, Acadia Pharmaceuticals Inc. has gained 151.39% as of 01/25/2016's recent price of $37.91.
If you would have followed this Deutsche Securities's recommendation on ACAD, you would have gained 151.39% of your investment in 3079 days.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company is developing a portfolio consisting of its four product candidates, including pimavanserin, which is in Phase III development for the treatment of Parkinson?s disease psychosis. In addition, the Company has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, Inc., and ACP-106 in IND-track development. The Company?s product candidates include Pimavanserin, AGN-XX/YY, AC-262271 and ACP-106. The Company maintains two wholly owned subsidiaries: ACADIA Pharmaceuticals AB based in Malmo, Sweden and ACADIA Pharmaceuticals A/S based in Denmark.

Deutsche Bank's award-winning Research team manages a range of functions from asset allocation, through economic forecasting across a broad range of industry sectors including cement and construction, chemicals, electronics, energy, engineering, machinery, media, software, tobacco, retailing and utilities, and oil and gas.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/21/2007 9:25 AM Buy
None
15.08 18.00
as of 8/27/2015
1 Week down  -3.14 %
1 Month down  -11.67 %
3 Months down  -2.91 %
1 YTD up  51.70 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy